A range of recent human and preclinical studies has uncovered the synergistic potential of Unigen’s two branded joint health nutraceuticals, AmLexin and Univestin, to manage symptoms and address the root cause of osteoarthritis.
The botanical blend, which has been launched as ArthroLexin, combines the heartwood of Acacia catechu with the root bark of Morus alba and Chinese skullcap (Scutellaria baicalensis).
Sourced from Traditional Chinese Medicine (TCM) and Ayurvedic roots, AmLexin and Univestin support joint health synergistically by modulating the cellular mechanisms involved in osteoarthritis’s disease pathology.
By combining these ingredients, Unigen claims it has created a solution that can not only improve mobility and reduce pain in those with osteoarthritis — better than ibuprofen — but also tackle the root cause of the symptoms: cartilage degradation.
To get to the bottom of how ArthroLexin can benefit joint health in the ageing community, the science behind its efficacy and how the nutraceutical industry can address patient needs that pharma currently can’t, NBR spoke with Qi Jia, Chief Science Officer at Unigen.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.
